FI3119911T3 - Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa - Google Patents
Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa Download PDFInfo
- Publication number
- FI3119911T3 FI3119911T3 FIEP15764560.7T FI15764560T FI3119911T3 FI 3119911 T3 FI3119911 T3 FI 3119911T3 FI 15764560 T FI15764560 T FI 15764560T FI 3119911 T3 FI3119911 T3 FI 3119911T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- patient
- formula
- apoe4
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 17
- 208000024827 Alzheimer disease Diseases 0.000 title claims 7
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 108700028369 Alleles Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 229960003570 tramiprosate Drugs 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000003205 genotyping method Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968595P | 2014-03-21 | 2014-03-21 | |
| PCT/US2015/022058 WO2015143447A2 (en) | 2014-03-21 | 2015-03-23 | Methods for treating neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3119911T3 true FI3119911T3 (fi) | 2023-09-27 |
Family
ID=54145492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15764560.7T FI3119911T3 (fi) | 2014-03-21 | 2015-03-23 | Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10471029B2 (enExample) |
| EP (2) | EP3119911B1 (enExample) |
| JP (5) | JP6588962B2 (enExample) |
| KR (2) | KR102448386B1 (enExample) |
| CN (1) | CN106170563A (enExample) |
| AU (1) | AU2015230972B2 (enExample) |
| CA (1) | CA2941415A1 (enExample) |
| DK (1) | DK3119911T3 (enExample) |
| ES (1) | ES2960625T3 (enExample) |
| FI (1) | FI3119911T3 (enExample) |
| HR (1) | HRP20231172T1 (enExample) |
| HU (1) | HUE063369T2 (enExample) |
| LT (1) | LT3119911T (enExample) |
| PL (1) | PL3119911T3 (enExample) |
| PT (1) | PT3119911T (enExample) |
| RS (1) | RS64744B1 (enExample) |
| SI (1) | SI3119911T1 (enExample) |
| SM (1) | SMT202300369T1 (enExample) |
| WO (1) | WO2015143447A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3347002T2 (ro) | 2015-09-10 | 2023-10-31 | Alzheon Inc | Tratamentul bolii Alzheimer într-o populație specifică de pacienți |
| WO2018012596A1 (ja) * | 2016-07-13 | 2018-01-18 | 株式会社マイトス | 水素を有効成分として含む軽度認知障害又は認知症の予防又は治療用組成物 |
| CN108623501B (zh) | 2017-03-21 | 2022-04-19 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸衍生物及其用途 |
| CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
| CN110668980A (zh) * | 2018-07-03 | 2020-01-10 | 浙江京新药业股份有限公司 | 一种2-取代的高牛磺酸衍生物 |
| WO2020028290A1 (en) * | 2018-08-01 | 2020-02-06 | Alzheon, Inc. | Methods for treating neurodegenerative disorders |
| IL316611A (en) | 2018-08-01 | 2024-12-01 | Alzheon Inc | Sulfopropanoic acid derivatives for treating neurodegenerative disorders |
| CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
| PH12021553196A1 (en) | 2019-06-17 | 2022-11-07 | Alzheon Inc | Methods for treating neurodegenerative disorders |
| CN116059192B (zh) | 2019-11-13 | 2024-10-29 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| EP4514335A1 (en) | 2022-04-28 | 2025-03-05 | Alzheon, Inc. | Tramiprosate for treating apoe4-related diseases |
| CN120641092A (zh) | 2022-12-02 | 2025-09-12 | 阿尔泽恩股份有限公司 | 用于用曲米沙特治疗神经变性病症的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| KR100279898B1 (ko) * | 1992-10-13 | 2001-04-02 | 로버트 엘. 타버 | 알쯔하이머 질환의 검출방법 |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20060079578A1 (en) * | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| WO2005060393A2 (en) | 2003-08-11 | 2005-07-07 | California Institute Of Technology | Microfluidic large scale integration |
| CA2666246C (en) | 2006-10-12 | 2013-12-31 | Bellus Health (International) Limited | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| WO2008061795A2 (en) | 2006-11-24 | 2008-05-29 | Ac Immune Sa | N- (methyl) -1h- pyrazol- 3 -amine, n- (methyl) -pyridin-2-amine and n- (methyl) -thiaz0l-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's |
| US20120009125A1 (en) * | 2010-07-06 | 2012-01-12 | Lombard Jay L | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| US10449177B2 (en) | 2010-08-19 | 2019-10-22 | Buck Institute For Research On Aging | Methods of treating mild cognitive impairment (MCI) and related disorders |
| DK2994160T3 (da) | 2013-05-06 | 2019-08-12 | Baxalta Inc | Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g |
| JP6685912B2 (ja) * | 2014-02-08 | 2020-04-22 | ジェネンテック， インコーポレイテッド | アルツハイマー病治療方法 |
| MD3347002T2 (ro) | 2015-09-10 | 2023-10-31 | Alzheon Inc | Tratamentul bolii Alzheimer într-o populație specifică de pacienți |
| US20180250249A1 (en) | 2016-02-02 | 2018-09-06 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
-
2015
- 2015-03-23 CA CA2941415A patent/CA2941415A1/en active Pending
- 2015-03-23 ES ES15764560T patent/ES2960625T3/es active Active
- 2015-03-23 FI FIEP15764560.7T patent/FI3119911T3/fi active
- 2015-03-23 JP JP2017501145A patent/JP6588962B2/ja active Active
- 2015-03-23 PL PL15764560.7T patent/PL3119911T3/pl unknown
- 2015-03-23 HU HUE15764560A patent/HUE063369T2/hu unknown
- 2015-03-23 KR KR1020167027090A patent/KR102448386B1/ko active Active
- 2015-03-23 US US15/127,565 patent/US10471029B2/en active Active
- 2015-03-23 LT LTEPPCT/US2015/022058T patent/LT3119911T/lt unknown
- 2015-03-23 SI SI201531967T patent/SI3119911T1/sl unknown
- 2015-03-23 CN CN201580015086.8A patent/CN106170563A/zh active Pending
- 2015-03-23 DK DK15764560.7T patent/DK3119911T3/da active
- 2015-03-23 WO PCT/US2015/022058 patent/WO2015143447A2/en not_active Ceased
- 2015-03-23 EP EP15764560.7A patent/EP3119911B1/en active Active
- 2015-03-23 SM SM20230369T patent/SMT202300369T1/it unknown
- 2015-03-23 KR KR1020227033161A patent/KR102645633B1/ko active Active
- 2015-03-23 EP EP23189240.7A patent/EP4289820A3/en active Pending
- 2015-03-23 RS RS20230993A patent/RS64744B1/sr unknown
- 2015-03-23 AU AU2015230972A patent/AU2015230972B2/en active Active
- 2015-03-23 PT PT157645607T patent/PT3119911T/pt unknown
- 2015-03-23 HR HRP20231172TT patent/HRP20231172T1/hr unknown
-
2019
- 2019-01-29 JP JP2019012873A patent/JP2019065044A/ja not_active Withdrawn
- 2019-09-13 US US16/570,487 patent/US20200101031A1/en not_active Abandoned
-
2020
- 2020-04-02 JP JP2020066670A patent/JP2020109123A/ja not_active Withdrawn
-
2022
- 2022-07-29 US US17/877,380 patent/US20230087041A1/en active Pending
- 2022-08-22 JP JP2022131705A patent/JP2022159555A/ja active Pending
-
2024
- 2024-11-26 JP JP2024205572A patent/JP2025022992A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3119911T3 (fi) | Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa | |
| PH12016502103A1 (en) | Novel disubstituted 1,2, 4-triazine compound | |
| SG10201901242PA (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| WO2016210372A3 (en) | Methods to treat neurological diseases | |
| EA201490419A1 (ru) | Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| NZ712207A (en) | Tetrahydropyrrolothiazine compounds | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| PH12019501811A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| WO2017106429A3 (en) | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases | |
| ZA201802312B (en) | A group of compounds used for the treatment or prevention of hyperuricemia or gout | |
| BR112012016460A2 (pt) | diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica. | |
| NZ749427A (en) | Thiophene, manufacturing method thereof, and pharmaceutical application of same | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2017511377A5 (enExample) | ||
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| PH12016502568B1 (en) | Novel heterocyclic compound | |
| EP2792666A4 (en) | PHORBOL-TYPE DITERPENE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF VIRAL INFECTIOUS DISEASES COMPRISING THE SAME | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| WO2016122289A3 (ko) | 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물 | |
| TR201717703A2 (tr) | Api̇ksaban formülasyonlari | |
| WO2017034242A3 (ko) | 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물 | |
| HK1233927A1 (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use |